l

The content of this website is intended for healthcare professionals only

HIV antiretroviral drugs may lower multiple sclerosis risk

Significant implications for treatment of MS if link proves causal, say researchers

Caroline White

Tuesday, 05 August 2014

HIV infection seems to be linked to a significantly lower risk of developing multiple sclerosis, possibly as a result of the drugs used to treat the virus, indicates research* published online in the Journal of Neurology Neurosurgery & Psychiatry.

If subsequently found to be causal, this could have considerable implications for the treatment of MS, they suggest.

The researchers wanted to explore the link further in the footsteps of a Danish team who had attempted to find out if antiretroviral drugs might treat or slow the progression of MS.

They had done this after MS symptoms in an HIV positive man disappeared for more than 12 years following antiretroviral treatment for his HIV infection.

The Danish researchers’ results suggested that antiretroviral drugs might interfere with MS progression, but the numbers were too small to reach statistical significance, prompting the current researchers to carry out a much larger comparative study.

So they looked at episodes of hospital care between 1999 and 2011 in England

In all, more than 21,000 people infected with HIV were treated during this period, as were almost 5.3 million people treated for minor conditions or injuries, who acted as the comparison group.

The development of MS was tracked in all participants for seven years, with the actual number of cases arising compared with the number expected to have arisen in the population.

Compared with those who did not have HIV, those who did were 62% less likely to develop MS, based on seven actual diagnoses of MS during that period versus the 18 that would have been expected.

The degree of protection seemingly conferred by HIV increased the more time that elapsed between a diagnosis of HIV and one of MS, the analysis indicated.

After more than a year between the two diagnoses, HIV positive patients were 75% less likely to develop MS, based on four actual diagnoses versus the 16 that would have been expected.

And after more than five years this increased to 85%, based on one actual case versus the 6.5 that would have been expected.

The crucial difference between this latest study and the Danish research is that the new findings are statistically significant, say the researchers.

They emphasise that their findings can only be speculative rather than definitive, because the study is observational, added to which they have no information on whether the HIV positive participants had taken antiretroviral drugs, or for how long.

But they write: “If subsequent studies demonstrate there is a causal protective effect of HIV and/or its treatment, and if the magnitude of it proves to be similar…this would be the largest protective effect of any factor yet observed in relation to the development of MS.”

To explain the link they suggest that HIV infection may itself stave off the development of MS, or it could be that antiretroviral drugs to dampen down the proliferation of the virus may also have the same effect on other viral agents implicated in the development of MS.

In an accompanying editorial**, Mia van der Kop, an epidemiologist at the University of British Columbia in Vancouver, Canada, says the findings add to the body of evidence pointing to a link between HIV, or its treatment, and MS.

“However, additional work is required to move beyond hypothesis generation,” she cautions.

Dr Emma Gray, Research Communications Manager at the MS Society, said the study was “valuable and intriguing.”

But she added: “Much more research is needed to definitively prove whether having HIV or being treated for HIV with antiretrovirals, or even a combination of the two, reduces the risk of someone developing MS.” A London-based trial of one antiretroviral drug is under way, she added.


* Julian Gold, et al. HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. J Neurol Neurosurg Psychiatry doi:10.1136/jnnp-2014-307932

** Mia L van der Kop. Does antiretroviral therapy for HIV reduce the risk of developing multiple sclerosis? J Neurol Neurosurg Psychiatry doi:10.1136/jnnp-2014-308297

Registered in England and Wales. Reg No. 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Reg No. 30158470